Prevalence and correlates of HIV, syphilis, and hepatitis B and C infection and harm reduction program use among male injecting drug users in Kabul, Afghanistan: A cross-sectional assessment
© Todd et al; licensee BioMed Central Ltd. 2011
Received: 14 June 2011
Accepted: 25 August 2011
Published: 25 August 2011
A nascent HIV epidemic and high prevalence of risky drug practices were detected among injecting drug users (IDUs) in Kabul, Afghanistan from 2005-2006. We assessed prevalence of HIV, hepatitis C virus (HCV), hepatitis B surface antigen (HBsAg), syphilis, and needle and syringe program (NSP) use among this population.
IDUs were recruited between June, 2007 and March, 2009 and completed questionnaires and rapid testing for HIV, HCV, HBsAg, and syphilis; positive samples received confirmatory testing. Logistic regression was used to identify correlates of HIV, HCV, and current NSP use.
Of 483 participants, all were male and median age, age at first injection, and duration of injection were 28, 24, and 2.0 years, respectively. One-fifth (23.0%) had initiated injecting within the last year. Reported risky injecting practices included ever sharing needles/syringes (16.9%) or other injecting equipment (38.4%). Prevalence of HIV, HCV Ab, HBSAg, and syphilis was 2.1% (95% CI: 1.0-3.8), 36.1% (95% CI: 31.8-40.4), 4.6% (95% CI: 2.9-6.9), and 1.2% (95% CI: 0.5-2.7), respectively. HIV and HCV infection were both independently associated with sharing needles/syringes (AOR = 5.96, 95% CI: 1.58 - 22.38 and AOR = 2.33, 95% CI: 1.38 - 3.95, respectively). Approximately half (53.8%) of the participants were using NSP services at time of enrollment and 51.3% reported receiving syringes from NSPs in the last three months. Current NSP use was associated with initiating drug use with injecting (AOR = 2.58, 95% CI: 1.22 - 5.44), sharing injecting equipment in the last three months (AOR = 1.79, 95% CI: 1.16 - 2.77), prior incarceration (AOR = 1.57, 95% CI: 1.06 - 2.32), and greater daily frequency of injecting (AOR = 1.40 injections daily, 95% CI: 1.08 - 1.82).
HIV and HCV prevalence appear stable among Kabul IDUs, though the substantial number having recently initiated injecting raises concern that transmission risk may increase over time. Harm reduction programming appears to be reaching high-risk drug user populations; however, monitoring is warranted to determine efficacy of prevention programming in this dynamic environment.
Central Asia has been identified as a region of concern for expanding human immunodeficiency virus (HIV) epidemics largely driven by injecting drug use [1, 2]. Increased rates of drug use, particularly injecting use, in this region have been attributed to multiple factors, including high unemployment, political instability, and, predominantly, an increasing opiate supply from Afghanistan [2, 3]. Though Afghanistan's role as an opium producer is widely known, consumption within the country has received relatively less attention [4, 5]. Based on a 2009 national survey, approximately 2.7% of the adult population is estimated to use opiates, and both smoking and injection of heroin are believed to be increasing . The majority of drug use is concentrated in urban areas, particularly injecting use, where 20% of urban heroin users are estimated to inject . A 2007 mapping study estimated a total injecting drug user (IDU) population of 1465 across three Afghan cities, with 1261 in Kabul city .
In 2005-2006, we conducted a cross-sectional assessment of the seroprevalence of HIV and viral hepatitis among 464 Kabul IDUs . Although HIV prevalence was low at 3.1%, HCV prevalence was higher at 36%. Levels of lifetime risk behaviors were high, reflected by 50.4% having ever shared needles or syringes, and harm reduction program use was low, with only one participant reporting needle and syringe collection and distribution program (NSP) use [7, 8]. Since the 2006 study, drug use patterns and the number of drug users have changed, with the numbers of drug users, injectors, and those using heroin as their drug of choice increasing in 2009 . In this interval, the number and range of harm reduction services have also expanded, particularly in Kabul. In 2009, HIV prevalence among IDUs in Kabul was 3%, suggesting some stability in the environment since 2006 [7, 9]. This biobehavioral survey also noted that 98% of Kabul IDUs reported using a sterile needle at their last injection; however, the national drug use survey performed in 2009 indicated that 87% of IDUs reported lifetime needle sharing and that 60% reported their syringes had been used by between 2 and 5 people prior to their personal use [5, 9]. These data appear contradictory and clarification of injecting behaviors is needed, for which serial prevalence data may provide some objective measures.
The purpose of this manuscript is to describe the prevalence and correlates of HIV, syphilis, and hepatitis B and C and harm reduction program use among IDUs entering a cohort recruited in Kabul, Afghanistan between June, 2007 and March, 2009.
Kabul is the capital and largest city in Afghanistan, estimated to have a population of 2.8 million in 2008 . Kabul also has among the highest density of opium and heroin users and IDUs nationally . At the beginning of the recruitment period, three NSPs were operating as were two addiction treatment programs available at no cost. No methadone maintenance programs were operating during the enrollment period.
Participant Eligibility & Recruitment
IDUs aged 18 years or greater who had injected within the last 30 days and residing in Kabul were eligible for entry. Potential participants were recruited at sites within Kabul city frequented by drug users and through NSPs by trained study staff; no set sample size was employed for recruitment from either site. Recruitment at sites frequented by drug users was done as a variant on time-location sampling, as study staff were present for enrollment at each of four to five sites based on the number of potential participants present at those sites. Site selection was re-evaluated monthly as congregation sites frequently shifted for various reasons, such as police harassment. Further, study staff would regularly visit pharmacies throughout the city and inquire with harm reduction outreach workers and participants regarding new sites for IDU congregation. Sites were distributed throughout Kabul, but, for the majority of the enrollment period, were largely concentrated in the western sections of the city, consistent with reported and confirmed IDU presence throughout the study period. Potential participants were also approached at drop-in centers for the three harm reduction programs in Kabul; study staff enrolled or performed follow-up interviews for participants recruited at these sites one afternoon each week throughout the study. For this convenience sample, IDUs interested in participation accompanied staff to a private room at the harm reduction center or to the study office for explanation of the study and provision of informed consent. Due to low literacy rates, potential participants were asked a series of questions following presentation of the consent by study staff to ensure comprehension; fingerprint was provided in lieu of signature per participant preference. Potential participants declining entry were not enumerated nor was any information collected from these individuals. The institutional review boards of the Afghan Ministry of Public Health, University of California San Diego, and Columbia University approved the protocol.
Measurement of variables and outcomes of interest
The questionnaire instrument assessed sociodemographics, travel, incarceration and medical histories, drug use and sexual behaviors, and knowledge of infection transmission and prevention. Drug use behaviors of interest included sharing needles/syringes ever and in the last three months, sharing injecting "works" (e.g. cookers, cotton) ever and in the last three months, duration of injecting, injecting while incarcerated, aspirating and re-injecting blood (khoon bozee), and receiving assistance with injecting. Assistance with injecting was assessed with the question of whether anyone, including a group leader, had injected a given participant. Transition from smoking to injecting opiates or other substances was also specifically queried, as was geographic location of injecting initiation.
Sexual risk behaviors of interest were having used a condom at any sexual encounter, ever having sex with men or boys, and having patronized a female sex worker (FSW) ever and in the last three months. Other possible routes of transmission were also assessed, such as receipt of therapeutic injections.
The outcomes of interest were prevalence of HIV, syphilis, and hepatitis B and C infection and reported NSP program use. NSP program use at enrollment was defined as both current stated participation and reporting currently receiving syringes from a program.
Study staff were Afghan men who had worked with drug users through either harm reduction programs or through medical practice and included at least one physician at all times. Staff were trained in human subjects research, voluntary counseling and testing practices, phlebotomy and serum preparation, and questionnaire administration. The senior study managers throughout the project, both Afghan physician (MRS and AN), provided quality assurance in the field through instrument completion checks and direct observation.
Following informed consent, participants completed the interviewer-administered questionnaire, received pre-test counseling, and underwent whole blood rapid testing for HIV-1, syphilis, hepatitis B surface antigen (HBsAg), and hepatitis C antibody (HCV Ab) (all rapid tests from SD Bioline, Standard Diagnostics, Kyonggi-do, Korea). Participants with reactive rapid test results underwent intravenous sampling for confirmatory testing. Participants then received post-test counseling, hepatitis B vaccine as needed, and were scheduled for health education classes and follow-up tests results, as indicated. All participants completed four health education classes covering injection and sexual risk reduction, abscess prevention, and nutrition and hygiene. Basic hygiene supplies (e.g. soap, razor, toothbrush) were provided upon completion of the classes (value US$4), not advertised at the time of recruitment to avoid coercion.
All confirmatory testing was performed at the Afghan Public Health Institute laboratory in Kabul. Samples reactive for HIV on rapid test received Western blot confirmation (HIV Blot 2.2, Genelabs, Singapore). For hepatitis C, polymerase chain reaction (PCR) (Amplicor, Roche Diagnostics, Mannheim, Germany) was used to confirm infection with reflex RIBA (recombinant immunoblot assay) (Chiron RIBA 3.0 SIA, Chiron Company, Emeryville, California) employed for samples with no detectable virus. HBV confirmation was performed with PCR (Amplicor, Roche Diagnostics, Mannheim, Germany) for reactive specimens. Syphilis infection was confirmed with Treponema pallidum plasma agglutinin assay (TPPA) (Fujirebio, Wilmington, DE, USA), with rapid plasma reagin (RPR) titre (Inverness Medical, Princeton, NJ, USA) for guidance of clinical decision-making. Participants were encouraged to follow up for confirmatory tests results but were not actively sought to preserve confidentiality.
Treatment referrals were provided for participants with confirmed cases of HIV, hepatitis B, and/or C receiving test results to sites within the public health system providing antiretroviral therapy and hepatitis supportive care. Confirmed syphilis cases with RPR titre≥1:4 were offered treatment with intramuscular benazathine penicillin per international treatment guidelines .
The target sample size for cohort entry was 450, sufficient to detect at least a 16% difference in needle sharing over time with 80% power (two-sided alpha = 0.05). Descriptive statistics for the study population were generated. Prevalence and confidence intervals for each infection were calculated with Poisson or binomial distribution as appropriate. Prevalence of NSP use at baseline was measured with simple proportions.
Univariable logistic regression was performed to identify potential associations between outcomes of interest and select demographic and risk behavior variables. Variables were entered into a multiple model if they were associated at the 10% level in univariable analysis or were considered of epidemiologic significance; entry into the final model was determined by likelihood ratio test at a significance level <0.10. All analysis was performed with Stata Version 10.0 (Stata Corporation, College Station, Texas).
Participant and Drug Use Characteristics
Demographic and key risk behavior characteristics of male injecting drug users enrolled into a longitudinal cohort study in Kabul, Afghanistan (N = 483)
Level of education (years)
Age initiated injecting (years)
21 - 29
Duration of injecting (years)
1 - 6
Number of daily injections
5 - 6
Born in Afghanistan
Lived outside Afghanistan in last 5 years
Employed at enrollment
Initiated drug use with injecting
Initiated injecting in the last year
Initiated injection inside Afghanistan
Ever shared needles/syringes
Shared needles/syringes in last 3 months
Ever shared injecting equipment
Shared injecting equipment in last 3 months
Ever inject/re-aspirate blood (khoon bozee)
Prior addiction treatment
Ever paid woman for sex*
Ever had sex with another male*
Ever used condom*
Heroin mixed with avil (76.8%) or with water or lemon juice (22.3%) were the most frequent drug preparations reportedly used in the month prior to enrollment. Use of other pharmaceutical preparations for injection was exceedingly rare, as only five participants mentioned using benzodiazepines or phenobarbital in combination with heroin and no participants mentioned using pharmaceutical agents alone in the last month. Other injecting risk behaviors, including lifetime and recent needle/syringe and injecting equipment sharing and aspirating and re-injecting blood (khoon bozee), were common (Table 1). Generally, Afghanistan was the site for injecting initiation although about one-third initiated injecting as a refugee.
Prevalence and Correlates of Infections
Variables independently associated with HIV and hepatitis B and C infection in logistic regression analysis among a cohort of male injecting drug users in Kabul, Afghanistan (N = 483)
Adjusted Odds Ratio
Ever share needles or syringes
1.58 - 22.38
Initiated injecting outside Afghanistan*
0.83 - 14.27
Hepatitis B Virus:
1.00 - 1.01
Current needle and syringe program use
0.14 - 0.94
Hepatitis C Virus:
Ever have abscess at injecting site
1.33 - 3.70
Ever share needles or syringes
1.38 - 3.95
Initiated injecting outside Afghanistan
1.26 - 3.04
Frequency daily injections (# injections)
1.11 - 1.94
Duration of injecting (per year)
1.00 - 1.10
Age (per year)
1.01 - 1.07
Prevalence and Correlates of NSP Service Use
Variables associated with needle and syringe program (NSP) use at enrollment among male IDUs in Kabul, Afghanistan in univariable and multivariable logistic regression analysis (N = 483)
(N = 258)
(N = 222)
OR, 95% CI
Frequency of daily injection
1.43, 1.12 - 1.82
Lived outside last 5 years
0.66, 0.45 - 0.97
1.51, 1.04 - 2.19
Share injecting works last 3 mos
1.67, 1.11 - 2.53
Initiate drug use with injecting
2.34, 1.14 - 4.83
Perceived need for addiction therapy
0.17, 0.04 - 0.76
Receipt of prior addiction treatment*
1.66, 0.98 - 2.82
Homeless at enrollment*
1.47, 0.95 - 2.28
Initiated drug use with injecting
1.22 - 5.44
Shared injecting works in last 3 months
1.16 - 2.77
1.06 - 2.32
Frequency of daily injection
1.08 - 1.82
Lived outside Afghanistan in the last 5 years
0.41 - 0.91
Perceived need for addiction treatment
0.03 - 0.70
The HIV, HCV, and HBV prevalence detected among Kabul IDUs from 2007 to 2009 was not substantially different from prevalence estimates obtained in 2006 . Though factors believed to predispose to a rapid epidemic, such as poverty, unemployment, and insecurity have been consistently present, the explosive increase in HIV prevalence noted between annual cross-sectional studies in Pakistan and other settings has not yet occurred [12–14].
The association between HIV and HCV and lifetime needle or syringe sharing is consistent with 2006 findings and potentially indicates a sustained level of risk behavior among the population. However, reported recent sharing of either needles/syringes or injecting works were not associated with either infection. The reported levels of lifetime and recent sharing among Kabul IDUs in 2006 were much higher, as 50.4% reported ever sharing needles or syringes and 31% reported sharing injecting equipment in the six months prior to enrollment [7, 15]. We hypothesize that harm reduction service expansion and inclusion of field-based NSP services has both decreased sharing and increased HIV transmission knowledge. However, the large decrease in reported lifetime sharing may indicate also that sharing is becoming a stigmatized behavior and is subsequently under-reported. The national drug use survey from 2009 reported lifetime needle sharing of 87% among IDUs; this survey included rural areas and noted a concentration of injecting in the southern provinces . Few harm reduction programs operate in these provinces, where the population is predominantly rural, limiting the ability to disseminate information on the dangers of needle sharing. Since needle and syringe sharing remained strongly associated with prevalent HIV and HCV, there remains room for improvement in terms of harm reduction expansion in Kabul.
Initiating injecting outside Afghanistan was also associated with both HIV and HCV infection, likely reflecting increased likelihood of transmission in neighboring countries with higher HCV and HIV prevalence (e.g. Iran, Pakistan) [13, 16]. The 2005 Kabul study did not assess where drug use and injecting were initiated, though injecting was assumed to be a behavior acquired outside Afghanistan . As Afghans living as refugees may not have the same access to harm reduction/NSP services in countries of refuge, sharing needles and syringes may have been more likely, as observed in Iran .
HCV was associated with history of injection site abscess, potentially reflecting rushed injecting which may be a proxy measure for sharing of equipment [18, 19]. In formative work, IDUs stated that relative speed of administration and ability to conceal use, particularly from police, were possible reasons for initiating injecting . This same rationale may exist for rushed injecting. Having had an abscess at the injection site within the last year was associated with HCV antibody among IDUs in the United Kingdom in a cross-sectional study,  but a similar association was not observed in a Canadian study .
HBV infection was not associated with sharing needles/syringes or injecting in prison, as in 2006, but was negatively associated with current NSP use. As HIV and HCV were not associated with NSP use, it seems less likely that this may be a proxy for fewer risky sharing behaviors. However, the recent expansion of NSPs in Kabul and the greater virulence and ease of transmission associated with HBV may provide an earlier sign of positive behavior change associated with NSP use; forthcoming incidence data will be assessed for impact of NSP use on HBV and other infection incidence over time.
There was higher reported lifetime use of harm reduction programs, specifically NSP services, than measured in the 2006 study. As data presented here and in 2006 are cross-sectional and utilized convenience sampling, some of this difference may be attributed to undersampling NSP users in 2006 or oversampling this group during cohort recruitment. However, an increased number of harm reduction programs and introduction of primary exchange services in the field, now the preferred method for NSP delivery, have debuted and may contribute to this change .
Current NSP users represent IDUs who, in many respects, are at greater risk for blood-borne infection due to initiating drug use with injecting, recent sharing of injecting equipment, and more frequent injecting daily. That IDUs using NSP services are more likely to have risky injecting practices has been noted in other settings, such as the United Kingdom and Canada [23–25]. The data indicate that these services are reaching their target clientele; however, service delivery in this setting is a work in progress and efficacy remains an open question. NSP users were substantially less likely to perceive great need for treatment, potentially indicating NSP use is an entrée to addiction treatment. This relationship has been established in other settings and several harm reduction programs in Kabul have incorporated abstinence-based treatment programs [26, 27]. As opioid substitution treatment (OST) is scaled up, harm reduction programs will need to ensure that linkages remain in place to treatment [26–28]. Further, programs should incorporate a low threshold model consistent with harm reduction rather than an abstinence based approach which has unrealistic expectations regarding the recovery process. The negative association between NSP use and having lived outside the country in the last five years may represent difficulties experienced by recently-repatriated IDUs in accessing services of which they may not be aware.
This study has several limitations. Participants were enrolled over a lengthy period by convenience sampling and may not be representative of IDUs in Kabul. Further, no data were recorded on those ineligible or declining entry, potentially leading to under-representation of hidden or isolated groups. We elected not to use respondent-driven sampling or other chain-referral methods in this setting for two reasons. First, based on qualitative work preceding cohort enrollment in Kabul, drug users perceive that injection drug use results in better services and greater opportunities for compensation . Memorably, we were informed by one participant that press photographers would pay IDUs to be photographed or videotaped while injecting. By choosing and compensating seeds and recruits, we were concerned that drug users might inadvertently initiate injecting due to compensation, which may weigh on perceived ability to meet basic needs in this impoverished setting . Similar concerns have been voiced by researchers in Lebanon . We did not monetarily compensate our participants and also ensured that medical care, including VCT services and naloxone, were available to non-participants upon request. Next, in insecure environments where frequent migration outside and within the city occurs, networks are transient and assignment of seeds may not guarantee recruit derivation from the same network. This network fragility may then prompt "seeds" to recruit IDUs unknown to them, compromising the validity of RDS and increasing risk for coercive practices between seed and recruiter.
Socially desirable response may have occurred, particularly with sensitive behaviors; we attempted to reduce this through staff familiar to the participant population and providing choice as to location of the study interview. Though audio computer-assisted survey interviewing has been noted to improve self-reporting among IDUs, this technology was not financially possible or feasible in this environment where there was often no power and the team was largely field-based . HIV-related analyses were underpowered due to low prevalence, potentially masking some associations. There were no female IDUs enrolled, precluding characterization. Female IDUs exist in Kabul but access to this hidden group has been elusive as the few women using harm reduction services are not injectors and require home visits due to cultural proscriptions.
In summary, both injecting drug use and NSP utilization appear to be increasing in Kabul, Afghanistan. Injecting has become an accepted and popular route of drug administration, tied to many factors, with the ready availability of heroin among the most important. The apparent stability of HIV and HCV prevalence between an earlier study and this cohort at baseline may be offset by influx of new injectors and environmental factors favoring an explosive epidemic. Harm reduction program and NSP use appear acceptable and efforts to improve service quality and scale up effective interventions, particularly OST, are urgently needed.
The following abbreviations are used within the manuscript text
Hepatitis B surface antigen
Hepatitis C virus
- HCV Ab:
Hepatitis C antibody
Human immunodeficiency virus
Injecting drug user
Needle and syringe distribution and collection program
Opioid substitution treatment
polymerase chain reaction
Recombinant immunoblot assay
Rapid plasma regain
Treponema pallidum plasma agglutination.
We thank colleagues at the harm reduction programs of Medicins du Monde, Nejat Center, and OTCD for their collaborative efforts. We also acknowledge the support of the Ministries of Counter-Narcotics and Public Health. Last, we thank our participants for their time, input, and trust. This study was funded by a Clinical Scientist Development Award from the Doris Duke Charitable Foundation.
- Joint United Nations Programme on HIV/AIDS (UNAIDS): Report on the global AIDS epidemic. 2008, Geneva, Switzerland, UNAIDSGoogle Scholar
- Thorne C, Ferencic N, Malyuta R, Mimica J, Niemiec T: Central Asia: hotspot in the worldwide HIV epidemic. Lancet Infect Dis. 2010, 10: 479-88. 10.1016/S1473-3099(10)70118-3.View ArticlePubMedGoogle Scholar
- Beyrer C, Wirtz AL, Baral S, Peryskina A, Sifakis F: Epidemiologic links between drug use and HIV epidemics: an international perspective. J Acquir Immune Defic Syndr. 2010, 55 (Suppl 1): S10-6.View ArticlePubMedGoogle Scholar
- United Nations Office on Drugs and Crime (UNODC): Afghanistan Drug Use Survey 2005. 2006, Kabul, Afghanistan: UNODC Afghanistan OfficeGoogle Scholar
- UNODC: Afghanistan Drug Use Survey 2009: Executive Summary. 2010, Kabul, Afghanistan: UNODC Afghanistan OfficeGoogle Scholar
- The World Bank South Asia Region Human Development Sector: Mapping and Situation Assessment of Key Populations at High Risk of HIV in Three Cities of Afghanistan. Washington D.C.: World Bank ;. 2008, .Google Scholar
- Todd CS, Abed AM, Strathdee SA, Scott PT, Botros BA, Safi N, Earhart KC: Prevalence of HIV, hepatitis C, hepatitis B, and associated risk behaviors among injection drug users in Kabul, Afghanistan. Emerg Infect Dis. 2007, 13: 1327-1331.PubMed CentralView ArticlePubMedGoogle Scholar
- Todd CS, Abed AM, Scott PT, Safi N, Earhart KC, Strathdee SA: A cross-sectional assessment of utilization of addiction treatment among injection drug users in Kabul, Afghanistan. Subst Use Misuse. 2009, 44: 416-30. 10.1080/10826080802347669.View ArticlePubMedGoogle Scholar
- National AIDS Control Program, Ministry of Public Health, Islamic Republic of Afghanistan: UNGASS Country Progress Report: Afghanistan. 2010, Kabul, Afghanistan: Ministry of Public HealthGoogle Scholar
- Central Statistics Office: Afghanistan: Population. 2011, [http://cso.gov.af/en/page/1505]Google Scholar
- Workowski KA, Berman S, Centers for Disease Control and Prevention (CDC): Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep. 2010, 59: 1-110.PubMedGoogle Scholar
- Emmanuel F, Archibald C, Razaque A, Sandstrom P: Factors associated with an explosive HIV epidemic among injecting drug users in Sargodha, Pakistan. J Acquir Immune Defic Syndr. 2009, 51: 85-90. 10.1097/QAI.0b013e31819906f3.View ArticlePubMedGoogle Scholar
- Hankins CA, Friedman SR, Zafar T, Strathdee SA: Transmission and prevention of HIV and sexually transmitted infections in war settings: implications for current and future armed conflicts. AIDS. 2002, 16: 2245-2252. 10.1097/00002030-200211220-00003.View ArticlePubMedGoogle Scholar
- Griffin N, Khoshnood K: Opium trade, insurgency, and HIV/AIDS in Afghanistan: relationships and regional consequences. Asia Pac J Public Health. 2010, 22 (3 Suppl): 159S-167S.View ArticlePubMedGoogle Scholar
- Todd CS, Abed AM, Scott PT, Botros BA, Safi N, Earhart KC, Strathdee SA: Correlates of Receptive and Distributive Needle Sharing Among Injection Drug Users in Kabul, Afghanistan. Am J Drug Alcohol Abuse. 2008, 34: 91-100. 10.1080/00952990701764771.View ArticlePubMedGoogle Scholar
- Zamani S, Kihara M, Gouya M, Vazirian M, Ono-Kihara M, Razzaghi EM, Ichikawa S: Prevalence of and factors associated with HIV-1 infection among drug users visiting treatment centers in Tehran, Iran. AIDS. 2005, 19: 709-716. 10.1097/01.aids.0000166094.24069.72.View ArticlePubMedGoogle Scholar
- Ezard N, Oppenheimer E, Burton A, Schilperoord M, Macdonald D, Adelekan M, Sakarati A, van Ommeren M: Six rapid assessments of alcohol and other substance use in populations displaced by conflict. Confl Health. 2011, 5: 1-10.1186/1752-1505-5-1.PubMed CentralView ArticlePubMedGoogle Scholar
- Small W, Rhodes T, Wood E, Kerr T: Public injection settings in Vancouver: physical environment, social context and risk. Int J Drug Policy. 2007, 18: 27-36. 10.1016/j.drugpo.2006.11.019.View ArticlePubMedGoogle Scholar
- Lloyd-Smith E, Wood E, Zhang R, Tyndall MW, Montaner JS, Kerr T: Risk factors for developing cutaneous injection-related infection among injection drug users: a cohort study. BMC Public Health. 2008, 9: 405-View ArticleGoogle Scholar
- Todd CS, Stibich MA, Stanekzai MR, Rasuli MZ, Bayan S, Wardak SR, Strathdee SA: A qualitative assessment of injection drug use and harm reduction programmes in Kabul, Afghanistan: 2006-2007. Int J Drug Policy. 2009, 20: 111-20. 10.1016/j.drugpo.2007.11.022.View ArticlePubMedGoogle Scholar
- Hope V, Kimber J, Vickerman P, Hickman M, Ncube F: Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in England. BMC Infect Dis. 2008, 8: 120-10.1186/1471-2334-8-120.PubMed CentralView ArticlePubMedGoogle Scholar
- Maguet O, Majeed M: Implementing harm reduction for heroin users in Afghanistan, the worldwide opium supplier. Int J Drug Policy. 2010, 21: 119-21. 10.1016/j.drugpo.2010.01.006.View ArticlePubMedGoogle Scholar
- Craine N, Hickman M, Parry JV, Smith J, McDonald T, Lyons M: Characteristics of injecting drug users accessing different types of needle and syringe programme or using secondary distribution. J Public Health (Oxf). 2010, 32: 328-35. 10.1093/pubmed/fdp131.View ArticleGoogle Scholar
- Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR: Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001, 34: 180-7.View ArticlePubMedGoogle Scholar
- Hayashi K, Wood E, Wiebe L, Qi J, Kerr T: An external evaluation of a peer-run outreach-based syringe exchange in Vancouver, Canada. Int J Drug Policy. 2010, 21: 418-21. 10.1016/j.drugpo.2010.03.002.PubMed CentralView ArticlePubMedGoogle Scholar
- Strathdee SA, Celentano DD, Shah N, Lyles C, Macalino G, Nelson K, Vlahov D: Needle exchange attendance and health care utilization promote entry into detoxification. J Urban Health. 1999, 76: 448-460. 10.1007/BF02351502.PubMed CentralView ArticlePubMedGoogle Scholar
- Shah N, Celentano DD, Vlahov D, Stambolis V, Johnson L, Nelson KE, Strathdee SA: Correlates of enrollment in methadone maintenance programs differ by HIV-serostatus. AIDS. 2000, 14: 2035-43. 10.1097/00002030-200009080-00020.View ArticlePubMedGoogle Scholar
- Kidorf M, King VL, Neufeld K, Peirce J, Kolodner K, Brooner RK: Improving substance abuse treatment enrollment in community syringe exchangers. Addiction. 2009, 104: 786-95. 10.1111/j.1360-0443.2009.02560.x.View ArticlePubMedGoogle Scholar
- World Bank, Afghanistan: Afghanistan Economic Update. 2010, , [http://www.worldbank.org.af/WBSITE/EXTERNAL/COUNTRIES/SOUTHASIAEXT/AFGHANISTANEXTN/0,,contentMDK:22575307~pagePK:141137~piPK:141127~theSitePK:305985,00.html]Google Scholar
- DeJong J, Mahfoud Z, Khoury D, Barbir F, Afifi RA: Ethical considerations in HIV/AIDS biobehavioral surveys that use respondent-driven sampling: illustrations from Lebanon. Am J Public Health. 2009, 99: 1562-7. 10.2105/AJPH.2008.144832.PubMed CentralView ArticlePubMedGoogle Scholar
- Des Jarlais DC, Paone D, Milliken J, Turner CF, Miller H, Gribble J, Shi Q, Hagan H, Friedman SR: Audio-computer interviewing to measure risk behaviour for HIV among injecting drug users: a quasirandomised trial. Lancet. 1999, 353: 1657-1661. 10.1016/S0140-6736(98)07026-3.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.